COMPLIANCE CERTIFICATE FOR THE QUARTER ENDED SEPTEMBER 30 2022
(Pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015)
I, Dhaval Soni, Company Secretary and Compliance Officer, have examined the following compliance requirement of Zydus Lifesciences Limited (Company) and certify that the Company has maintained a Structured Digital Database (SDD) pursuant to provisions of Regulation 3(5) and 3(6) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (PIT Regulations):
Sr.
Compliance Requirement
Yes /
Observation/ Remark
No
No
1.
Whether the Company has a Structured Digital Database in
Yes
place?
2.
Whether control exists as to who can access the SDD for read
Yes
/ write alongwith the names and PAN of such person?
3.
Whether all the UPSI had been captured in the Database. If not
Yes
details of events that had not been captured and the reason
for the same?
4.
Whether the recipients were upfront informed that the
Yes
information which they will be receiving shortly is UPSI and the
entry has been captured in the Database prior to forwarding
the UPSI data. If not details of events that have not been
captured and the reason for the same?
5.
Whether nature of UPSI have been captured alongwith date
Yes
and time?
6.
Whether name of persons who have shared the information
Yes
has been captured along with PAN or any other identifier?
7.
Whether name of persons with whom information is shared
Yes
has been captured along with PAN or any other identifier?
8.
Whether the database has been maintained internally?
Yes
9.
Whether audit trail is maintained?
Yes
10.
Whether time stamping is maintained?
Yes
11.
Whether the database is non-tamperable?
Yes
12.
Any other measures to ensure non-tamperability of the
No
Not required.
Database?
Note: The information of the audit should cover the period when such information was inserted in the SDD upto the date of disclosure.
The number of days for which non-compliance was observed: Not Applicable
Further, I also confirm that the Company was required to capture 1 number of event during the quarter ended on September 30, 2022 and has captured 1 number of the said required event.
For, Zydus Lifesciences Limited
DHAVAL NARENDRA SONI
Digitally signed by DHAVAL NARENDRA SONI
Date: 2022.10.07 09:35:03 +05'30'
Dhaval N. Soni
Company Secretary & Compliance Officer
Date
:
October 7, 2022
Place
:
Ahmedabad
Attachments
Original Link
Original Document
Permalink
Disclaimer
Zydus Lifesciences Ltd. published this content on 07 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 October 2022 05:01:04 UTC.
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
ZYDUS LIFESCIENCES LIMITED 
